Johnson & Johnson signage at their campus in Raritan, New Jersey, US, on Thursday, June 6, 2024.
Gabby Jones | Bloomberg | Getty Images
Johnson & Johnson said on Wednesday its experimental psoriasis drug has shown superior skin clearance compared to Bristol Myers Squibb’s Sotyktu in two late-stage head-to-head trials.
J&J said its icotrokinra met both main and secondary goals and showed superiority to Bristol’s Sotyktu at multiple timepoints in adult patients in the two trials.
J&J is testing its oral drug in adult and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis, which is an immune-mediated condition characterized by thick, scaly patches or plaques.
Bristol’s Sotyktu is a FDA-approved drug.
About The Author
